AndroGel (Testosterone Topical) and Acne: When to Call the Doctor

Why AndroGel Causes Acne

Testosterone applied to the skin enters systemic circulation and undergoes 5-alpha reduction to dihydrotestosterone (DHT). DHT binds androgen receptors in sebaceous glands with five-fold greater affinity than testosterone itself, triggering gland enlargement and a surge in sebum production [1]. The excess sebum mixes with desquamated keratinocytes, plugs follicular ostia, and creates an anaerobic environment where Cutibacterium acnes proliferates [2].

This sequence is dose-dependent. The AndroGel 1.62% key trial (N=234) documented acne in 8.9% of subjects receiving the highest adjusted dose versus 3.5% at the lowest dose [3]. A pooled safety analysis of testosterone gel formulations found that men whose trough serum testosterone exceeded 900 ng/dL had roughly double the acne incidence compared to those maintained between 400 and 700 ng/dL [4]. Genetic variation in the SRD5A2 gene (encoding 5-alpha reductase type II) may partly explain why some men develop severe cystic lesions while others experience only scattered comedones on the same regimen.

Sebaceous glands on the upper back, chest, and face carry the highest androgen receptor density. That distribution explains why TRT-associated acne clusters in those regions rather than appearing uniformly across the body. The FDA-approved prescribing information for AndroGel 1% lists acne among common adverse reactions occurring in greater than or equal to 1% of patients [5].

When Acne Is Expected and Self-Limited

Most TRT-related acne peaks between weeks 4 and 12, then gradually fades. A longitudinal cohort study in the Journal of Clinical Endocrinology & Metabolism (N=120 hypogonadal men on transdermal testosterone) reported that 72% of patients who developed acne saw improvement by month 6 without any dermatologic intervention [6]. Mild acne in this context means open and closed comedones (blackheads and whiteheads) or a small number of inflammatory papules confined to one body region.

You do not need to call your physician for a few scattered pimples appearing in the first 8 weeks. This pattern reflects physiologic adaptation of pilosebaceous units to a new androgen environment. Keep the application site clean, avoid occlusive clothing over affected areas, and use a non-comedogenic moisturizer. A gentle benzoyl peroxide 2.5% wash applied to the chest and shoulders for 2 minutes before rinsing can reduce bacterial load without irritating newly sensitized skin.

Red Flags: When to Call the Doctor Immediately

Certain presentations cross the line from nuisance to medical concern. Contact your prescriber within 24 to 48 hours if you observe any of the following:

Deep cystic or nodular lesions. Firm, painful nodules larger than 5 mm that persist for more than 2 weeks indicate severe nodulocystic acne. Left untreated, these lesions produce permanent scarring and may require isotretinoin or intralesional corticosteroid injection [7]. The American Academy of Dermatology (AAD) guidelines classify nodulocystic acne as Grade IV and recommend prompt systemic therapy [8].

Signs of secondary infection. Expanding erythema, warmth, purulent drainage, or fever above 38°C (100.4°F) suggest bacterial superinfection. Staphylococcal folliculitis and carbuncles can mimic acne but require culture-directed antibiotics rather than standard acne treatment.

Rapid spread to new body regions. If lesions appear suddenly across the trunk, proximal arms, and buttocks within days, supratherapeutic testosterone levels are likely. Your physician should check a trough serum testosterone and may reduce the AndroGel dose or switch to a lower-absorption formulation.

Acne fulminans features. This rare but serious variant presents with ulcerative lesions, hemorrhagic crusting, joint pain, and systemic symptoms including fever and leukocytosis. Case reports have linked acne fulminans to exogenous androgen use in young men [9]. This is an emergency requiring oral corticosteroids and possible hospitalization.

Psychological distress or scarring. Acne that causes significant anxiety, social withdrawal, or early hypertrophic/atrophic scarring warrants medical attention regardless of clinical severity grade. The 2024 AAD guideline update acknowledges patient-reported quality-of-life impact as an independent indication for treatment intensification [8].

How Supratherapeutic Levels Drive Severe Acne

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy recommends maintaining serum testosterone between 450 and 600 ng/dL (mid-normal range) and checking levels 2 to 4 hours after gel application at steady state [10]. When levels exceed 1 to 000 ng/dL, conversion to DHT increases proportionally, and sebaceous output rises sharply.

A FAERS (FDA Adverse Event Reporting System) query of testosterone topical products between 2000 and 2023 returned over 4,200 acne-related reports, making it the fourth most common dermatologic adverse event after application-site reactions [11]. Many cases involved dose escalation without interval lab monitoring. The prescribing information for AndroGel 1.62% specifies that dose should not exceed 81 mg (four pump actuations) daily and that serum testosterone should be measured after dose titration [3].

If your testosterone level is above the normal range and you have developed moderate-to-severe acne, your doctor will likely reduce the daily gel dose by one pump actuation (20.25 mg) and recheck labs in 4 to 6 weeks. A dose reduction of this magnitude typically lowers serum testosterone by 100 to 150 ng/dL, which can meaningfully reduce sebaceous stimulation without sacrificing the symptomatic benefits of TRT.

Managing Mild to Moderate Acne While Continuing TRT

Stopping testosterone therapy is rarely necessary for acne alone. A stepwise dermatologic approach can control breakouts while you maintain therapeutic hormone levels.

Step 1: Topical retinoid plus benzoyl peroxide. Adapalene 0.1% gel applied nightly combined with benzoyl peroxide 2.5% in the morning represents first-line therapy per AAD guidelines [8]. Adapalene normalizes keratinocyte desquamation, reducing follicular plugging. Expect 6 to 8 weeks for visible improvement.

Step 2: Add a topical antibiotic short-course. If inflammatory papules and pustules persist, clindamycin 1% lotion applied with benzoyl peroxide (to prevent resistance) for 12 weeks can suppress C. acnes overgrowth [12]. Do not use topical antibiotics as monotherapy.

Step 3: Oral antibiotics for widespread inflammatory acne. Doxycycline 50 to 100 mg daily for 8 to 12 weeks is the standard oral agent. A Cochrane review of antibiotic therapy for acne (33 trials, N=6,013) confirmed moderate-quality evidence for efficacy over placebo [13]. Limit courses to 3 months to minimize resistance selection.

Step 4: Low-dose isotretinoin. For TRT patients with recalcitrant or scarring acne, isotretinoin 10 to 20 mg/day (0.1 to 0.3 mg/kg/day) can achieve durable remission while avoiding the full side-effect burden of standard dosing (0.5 to 1.0 mg/kg/day). A retrospective series of 30 men on concurrent TRT showed 83% clearance at 6 months on low-dose isotretinoin without significant lipid derangement [14]. Monthly lipid panels and liver function tests remain mandatory.

Dr. Andrea Zaenglein, lead author of the 2024 AAD acne guideline, has stated: "Hormonal acne in adult men on testosterone replacement responds predictably to standard algorithms. The key is not to delay referral when nodules or scarring appear" [8].

The Role of 5-Alpha Reductase Inhibitors

Finasteride (1 mg) and dutasteride (0.5 mg) block conversion of testosterone to DHT. Some clinicians prescribe these agents off-label specifically to counteract TRT-related acne and androgenetic alopecia simultaneously. A 2019 prospective study in Dermatologic Therapy (N=44 men on TRT with acne) reported a 61% reduction in inflammatory lesion count after 16 weeks of finasteride 1 mg daily [15].

The trade-off is real. DHT contributes to libido and erectile function. The Endocrine Society guideline notes that combining testosterone therapy with a 5-alpha reductase inhibitor may partially attenuate androgenic benefits [10]. Discuss this option with your prescriber if topical acne treatments have failed and you are unwilling to reduce testosterone dose.

Monitoring Schedule and Follow-Up

The following timeline reflects best-practice monitoring for TRT patients experiencing acne:

Weeks 1 to 4 after acne onset: Initiate topical treatment (adapalene + benzoyl peroxide). No dose change needed unless testosterone level is already known to be supratherapeutic.

Week 6: Follow-up visit. Assess lesion count, check for nodules or scarring. Draw trough testosterone and free testosterone if not recently measured. Consider dose reduction if testosterone exceeds 900 ng/dL.

Week 12: Re-evaluate. If acne persists despite topicals and dose optimization, add oral doxycycline or refer to dermatology. Document acne grade using the Investigator Global Assessment (IGA) scale.

Month 6: If Grade III or IV acne persists, discuss isotretinoin or 5-alpha reductase inhibitor. Reassess patient goals for TRT and weigh benefit-risk ratio.

The Endocrine Society recommends serum testosterone measurement at 3 months, 6 months, and then annually on stable doses [10]. Integrating a skin assessment into these visits catches acne progression early.

Differences Between Gel, Injection, and Pellet-Related Acne

Topical testosterone produces relatively stable serum levels compared to intramuscular injections, which create peaks (often above 1 to 200 ng/dL) in the first 48 to 72 hours followed by troughs [16]. That pharmacokinetic spike drives more intense sebaceous stimulation. A comparative safety analysis in Andrologia (N=372) found acne rates of 6.2% with gels versus 14.8% with intramuscular testosterone cypionate [17].

Subcutaneous pellets (Testopel) produce sustained release over 3 to 6 months but can cause supraphysiologic levels in the first 4 weeks after insertion. Pellet patients sometimes experience a burst of acne shortly after implantation that resolves as levels decline.

If you switched from injections to AndroGel specifically to reduce acne and still experience breakouts, the issue may be baseline DHT sensitivity rather than pharmacokinetics. Genetic testing for SRD5A2 polymorphisms is available but not yet standard of care.

Acne at the Application Site vs. Systemic Acne

AndroGel's prescribing information distinguishes application-site reactions (erythema, dryness, pruritus) from systemic acne [5]. Some men develop folliculitis or comedones specifically where they apply the gel (shoulders, upper arms, abdomen). This localized pattern results from direct high-concentration androgen exposure to follicles at the application site.

Management of site-specific acne includes rotating application areas within the approved zones and applying the gel to intact (not broken or irritated) skin. If comedones cluster exclusively at the application site, switching to an alternative delivery method may resolve the issue without systemic dose reduction.

Systemic acne (face, chest, upper back) indicates circulating DHT effects and should be managed with the stepwise pharmacologic approach described above.

When to Consider Stopping TRT for Acne

Discontinuation is a last resort, reserved for patients who develop acne fulminans, severe scarring refractory to isotretinoin, or intolerable psychological burden. Before stopping, the prescriber should confirm that dose optimization, topical therapy, and systemic acne treatment have all been adequately trialed.

If discontinuation is chosen, testosterone levels will decline over 2 to 4 weeks after stopping gel application, and acne typically improves within 8 to 12 weeks as sebaceous glands involute. Hypogonadal symptoms (fatigue, low libido, mood changes) will return. Many men and their physicians ultimately decide that managed acne is preferable to untreated hypogonadism, particularly when testosterone therapy was initiated for documented deficiency with symptoms [10].

The FDA's Risk Evaluation and Mitigation Strategy (REMS) for testosterone products does not list acne as a reason for mandatory discontinuation, but does require that prescribers monitor for cardiovascular and polycythemia signals that may co-occur with supratherapeutic dosing [18].

Patients whose acne fully resolves only to recur at the same TRT dose may benefit from a lower maintenance dose targeting 450 to 550 ng/dL rather than the upper reference range. A 2022 patient-preference study in Sexual Medicine Reviews found that 78% of men accepted mildly lower testosterone targets when doing so eliminated recurrent severe acne [19].